Opinion|Videos|July 31, 2023
Enfortumab Vedotin Plus Pembrolizumab in Patients With Advanced Urothelial Carcinoma and an FGFR Mutation
Key opinion leaders discuss the available data on combination enfortumab vedotin plus pembrolizumab for the treatment of patients with metastatic or locally advanced urothelial carcinoma and an FGFR mutation.
Advertisement
Episodes in this series
Advertisement
Related to this article
Durvalumab plus enfortumab vedotin improved EFS and OS in MIBC and will be considered for FDA approval in the fourth quarter of 2026.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
CEPHEUS and Frontline Treatment in Newly Diagnosed Multiple Myeloma
5